Agios is a biopharmaceutical company passionately committed to applying our scientific leadership in the field of cellular metabolism to transform the lives of patients with cancer and inborn errors of metabolism (IEMs), which are a subset of orphan genetic metabolic diseases. Metabolism is a complex biological process involving the uptake and assimilation of nutrients in cells to produce energy and facilitate many of the processes required for cellular division and growth. We believe that dysregulation of normal cellular metabolism plays a crucial role in many diseases, including certain cancers and IEMs. We believe Agios is a first mover in using cellular metabolism, an unexploited area of biological research with disruptive potential, as a platform for developing potentially transformative medicines. Our singular focus is to apply our expertise in cellular metabolism to develop innovative small molecule treatments for cancer and IEMs. We intend to apply our deep understanding of metabolism, coupled with our ability to create medicines that can inhibit or activate metabolic enzymes, to fundamentally change the way cancer and IEMs are treated. We have identified and validated novel and druggable targets in both cancer and IEMs.

Research Grants show all

NIH2

Patents show all

295Applications50Issued

Clinical Trials show all

12Phase 12Phase 1/Phase 21N/A1Phase 21Phase 3

SEC Filings show all

8-K6010-Q1110-K3D3S-11

Private Funding Events

DateOfferedSoldType
2011-11-22$78,000,001$78,000,001Equity
2010-04-26$8,823,937$8,823,937Equity
2008-07-01UnknownUnknownOther (Paper Filing)

Key Executives

  • David Schenkein
    Executive Officer
  • Duncan Higgons
    Executive Officer
  • Robert Nelsen
    Director
  • Doug Cole
    Director
  • Lewis C. Cantley
    Director
  • Kevin Starr
    Director
  • John Maraganore
    Director
  • Marc Tessier-Lavigne
    Director
  • Perry Karsen
    Director